ArticleInternational journal of clinical practice2006
Lercanidipine is an effective and well tolerated antihypertensive drug regardless the cardiovascular risk profile: The LAURA study.
Article in International journal of clinical practice, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 44 citations in OpenAlex.
- Trial
- High doses of lercanidipine are better tolerated than other dihydropyridines in hypertensive patients with metabolic syndrome: results from the TOLERANCE study.International journal of clinical practice · 2008Trial
- Thiazole-Substituted Benzoylpiperazines with Anti-Cancer and Anti-Inflammatory Activities: Comparative Evaluation with Lercanidipine.International journal of molecular sciences · 2026Article
- Lercanidipine Enhances Cisplatin Activity: Dual Anticancer and Anti-Inflammatory Effects via Caspase Activation and MAPK Inhibition.Pharmaceuticals (Basel, Switzerland) · 2025Article
- New Insights into the Nephroprotective Potential of Lercanidipine.International journal of molecular sciences · 2023Review
- Development of a list with renally relevant drugs as a tool to increase medicines optimisation in patients with chronic kidney disease.European journal of hospital pharmacy : science and practice · 2023Article
- Calcium channel blocker lercanidipine electrochemistry using a carbon black-modified glassy carbon electrode.Analytical and bioanalytical chemistry · 2020Article
- Combination therapy with lercanidipine and enalapril in the management of the hypertensive patient: an update of the evidence.Vascular health and risk management · 2016Review
- Anti-inflammatoryactivity of calciumchannel blocker lercanidipine hydrochloride.Journal of pharmacology & pharmacotherapeutics · 2013Article
- Fixed combination of lercanidipine and enalapril in the management of hypertension: focus on patient preference and adherence.Patient preference and adherence · 2012Article
- Emerging drug combinations to optimize renovascular protection and blood pressure goals.International journal of nephrology and renovascular disease · 2012Article
- Mitigation of calcium channel blocker-related oedema in hypertension by antagonists of the renin-angiotensin system.Journal of human hypertension · 2009Review
- Fixed combinations in the management of hypertension: perspectives on lercanidipine-enalapril.Vascular health and risk management · 2008Review
- Lercanidipine in the Management of Hypertension: An Update.Journal of pharmacology & pharmacotherapeuticsReview
Corrections and comments
- Erratum issued
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To determine whether the antihypertensive effectiveness of lercanidipine was independent of the different cardiovascular risk levels. Patients with treated or untreated mild-to-moderate essential hypertension were included in a multicentre, prospective, non-comparative, open-label study. Patients received lercanidipine (10 mg/day, uptitrated to 20 mg/day) during 6 months. A total of 3175 patients, age 63 +/- 10 years, 51% women, were included. The cardiovascular risk was low in 237 patients, medium in 1396, high in 722, and very high in 820. At baseline, blood pressure (BP) was 159.5 +/- 11.7/95.2 +/- 7.4 mmHg. BP was progressively higher according to increase in cardiovascular risk. After 6 months of treatment, BP was 136.0 +/- 9.7/79.7 +/- 6.8 mmHg. The decrease in systolic BP and diastolic BP at each follow-up visit compared with baseline was statistically significant both in the intergroup and intragroup comparisons (p < 0.001). Mean decreases of systolic blood pressure (SBP) and diastolic blood pressure (DBP) were -18.5/-13.8 mmHg in the low risk group, -23/-15.2 mmHg in the medium risk group, -24.4/-16.1 mmHg in the high risk group, and -27.4/-17.4 mmHg in the very high risk group. Most frequent side effects were oedema (5.1%), headache (3.3%), flushes (2.5%), and asthenia (1%). Only 1.7% of patients discontinued antihypertensive medication because of adverse events. Tolerability of lercanidipine was independent of the cardiovascular risk group. Lercanidipine was effective and well-tolerated in patients with mild-to-moderate hypertension in the daily practice. The effectiveness and safety of the drug were independent of the degree of cardiovascular risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.